| P50 | author | Ulka Vaishampayan | Q86981393 |
| P2093 | author name string | Ulka Vaishampayan | |
| P2860 | cites work | Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma | Q27851979 |
| | Is mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients? | Q28075954 |
| | Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome | Q28219681 |
| | The somatic genomic landscape of chromophobe renal cell carcinoma | Q28246658 |
| | HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability | Q29615945 |
| | TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas | Q33688439 |
| | Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC) | Q33983198 |
| | Unclassified renal cell carcinoma: a clinicopathological, comparative genomic hybridization, and whole-genome exon sequencing study | Q34028996 |
| | Soft-tissue cryoablation in diffuse locations: feasibility and intermediate term outcomes | Q34262465 |
| | Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. | Q35188542 |
| | Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes | Q35810625 |
| | Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics | Q36354841 |
| | Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer | Q36413322 |
| | Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma | Q36642291 |
| | Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma | Q36646352 |
| | Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial | Q36932216 |
| | Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial | Q36932702 |
| | Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases | Q38740530 |
| | Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials. | Q38836367 |
| | The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies | Q38850221 |
| | Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. | Q38917870 |
| | First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. | Q39009124 |
| | Global Burden of Urologic Cancers, 1990-2013. | Q39060012 |
| | Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma | Q41508355 |
| | MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array | Q46111473 |
| | Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma | Q47574771 |
| | Renal medullary carcinomas: histopathologic phenotype associated with diverse genotypes | Q84512642 |
| | Savolitinib Heads for Phase III Trial in PRCC | Q88557400 |
| P433 | issue | 1 | |
| P304 | page(s) | 5 | |
| P577 | publication date | 2018-01-24 | |
| P1433 | published in | Current Treatment Options in Oncology | Q3510796 |
| P1476 | title | Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer | |
| P478 | volume | 19 | |